Inverna Therapeutics Launches as Leading RNA Therapeutics Company Focused on Huntington's Disease Treatment

Inverna Therapeutics, a new Danish biotech company, has launched to develop RNA therapeutics for severe genetic diseases. The company was co-founded by the University of Southern Denmark and Argobio and has a lead program addressing Huntington's disease. Inverna's platform originates from research by Professor Brage Storstein Andresen and aims to overcome limitations of conventional RNA therapeutics by harnessing the potential of sequence-based splice modulation.

Inverna Therapeutics, a groundbreaking Danish biotech company, was recently launched with the backing of the University of Southern Denmark and Argobio [1]. This new venture aims to develop innovative RNA therapeutics for severe genetic diseases, starting with a lead program addressing Huntington's disease.

Inverna's platform is based on the pioneering research of Professor Brage Storstein Andresen, an international expert in RNA splicing and antisense technology [1]. The company's unique approach harnesses the potential of sequence-based splice modulation to overcome limitations in conventional RNA therapeutics [1].

Splice modulation is a crucial aspect of gene expression, as it allows for the modification of pre-mRNA (pre-messenger RNA) before it is translated into proteins [2]. By manipulating this process, Inverna aims to provide safer and more effective treatments for a wide range of debilitating diseases [1].

Inverna's pseudo-exon targeting technology offers a potential solution to limitations in current RNA therapeutics by enabling precise, sequence-based, and allele-specific targeting with minimal off-target effects [1]. This approach could lead to significant advancements in the treatment of genetic diseases, as it allows for the targeted modification of specific disease-causing mutations.

Argobio, a leading European biotech start-up studio, has played a pivotal role in the establishment of Inverna Therapeutics [1]. With the initial investment, along with strategic guidance and operational expertise, Argobio has empowered Inverna to accelerate the development of its pipeline of innovative RNA therapeutics in a number of high-value indications [1].

In conclusion, Inverna Therapeutics represents a promising new paradigm in therapeutics, leveraging the power of RNA splicing modulation to develop innovative treatments for severe genetic diseases. With a strong foundation in groundbreaking research and the support of experienced industry partners, Inverna is well-positioned to make a significant impact on patient outcomes in this field.

References:
[1] Inverna Therapeutics. (2025, January 7). Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark. Retrieved from https://www.globenewswire.com/news-release/2025/01/07/3005115/0/en/Next-generation-RNA-company-Inverna-Therapeutics-launched-by-Argobio-and-University-of-Southern-Denmark.html
[2] National Center for Biotechnology Information. (2021). Splicing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK26862/